Imaging Skin Structure in Atopic Dermatitis Patients Using Light Scans
Uses light-based scans to study skin structure in people with atopic dermatitis.
Key facts
- Who runs it
- Sheffield Teaching Hospitals NHS Foundation Trust
- Where
- Sheffield, United KingdomSee the site
- Trial code
- Registry title
- Characterisation of Skin Microstructure Under Normal and Atrophied States
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 16 Jul 2024
- Planned end
- 1 Dec 2025
- Type of study
- Observational, 2 groups
- Record updated
- 1 May 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and people with atopic dermatitis who have used topical corticosteroids, to study skin structure with a non-invasive scan.
- Age
- 6 months or older.
- Sex
- Men and women can join.
- Disease stage
- For patients: atopic dermatitis, with a last flare at least 3 months ago and signs now controlled (ISGA 0-1, clear or almost clear).
- Earlier treatment
- For patients: at least 3 months of topical corticosteroid use (continuous or on and off) over the last 6 months. For healthy volunteers: no topical corticosteroid in the 6 months before the visit, except hydrocortisone for 4 weeks or less outside the target skin areas.
Main reasons for not taking part
- Acne, suntan, birthmarks, many moles, tattoos, blemishes or dense body hair on the measurement skin site
- Visible eczema or inflammation at the general measurement sites
- Healthy volunteers: history of chronic skin conditions (except acne)
- Any topical product on the measurement areas within 24 hours before the visit (more than 6 hours for patients with severe symptoms)
- Currently taking part in another interventional clinical trial
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Male or female aged ≥ 6 months old
- Volunteers understand the purpose, modalities, and potential risks of the study
- Volunteers are able to read and understand English
- Volunteers are willing to sign the informed consent
- [Patient cohort only] Patients diagnosed with AD and; A recent history of persistent signs (last flare ≥3 months); Currently controlled signs (ISGA 0-1; clear-almost clear); At least 3 months of TCS use (continuous or intermittent, over the last 6 months)
Who cannot take part
- Participants who have used any medication that could interfere with the trial aim prior to the start of the study (baseline/visit 1); [Healthy cohort only] Use of TCS at any point during the 6 months before the clinical visit (except hydrocortisone use for ≤4 weeks outside the target areas of skin)
- Use of any topical product on the measurement areas within 24 hours prior to the measurement visit (>6 hours for patients with severe symptoms)
- Participants with a condition that in the opinion of the investigator contradicts participation in the study; [Healthy cohort only] Participants with a history of chronic skin conditions (except acne)
- Participants with any of the following on the measurement skin site (acne, suntan, birthmarks, multiple nevi, tattoos, blemishes, or dense body hair that obstruct the test areas)
- Visible signs of eczema/inflammation at the general measurement sites. Excluding sites of specific interest (SSI) which are imaged in addition to the general measurement sites
- Volunteers currently participating in an interventional clinical trial
- Volunteers incapable of giving fully informed consent
- Volunteers judged by the PI to be inappropriate for the study
Where in United Kingdom
- Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS FTSheffield, United KingdomContact: Eva ZinconeTaking people
About the trial
What the trial wants to find out
Skin dermatoses are a major health concern around the world, with heavy economic, social, and psychological burdens. Due to their chronic and incurable nature, they are serious diseases that cause physical pain in patients and reduced quality of life. Atopic dermatitis is the most common inflammatory skin disease with a prevalence of almost 20% in children and 10% in adults. Current therapies are designed to control the condition rather than cure it. Therefore, these therapies are lifelong and, when the disease is flaring, must be used intensively to achieve control. Despite the emergence of various therapies, topical corticosteroids (TCS) remains the gold standard therapy generally used as a first-line treatment. However, if used inappropriately, it can act like a double-edged sword. With the beneficial action of TCS comes the potential for undesirable effects, like skin thinning, especially when used long-term or excessively.
Read full original descriptionShow less
The objective of this study is to define the normal structural parameters for healthy skin in a diverse cohort, determine the effect of age, sex, and ethnicity and subsequently study how these values differ in clinically abnormal skin resulting from excessive or inappropriate use of topical corticosteroids (TCS). This will be achieved by using optical coherence tomography (OCT) to non-invasively image the skin. By undertaking this study, the investigators will gain real-world insight into the effects of long-term TCS use on the skin.
The 2 groups in the trial
- Healthy
Participants with healthy skin and no history of skin diseases with the exception of acne.
- Atopic dermatitis
Participants with atopic dermatitis and signs of adverse skin changes caused by topical corticosteroid use.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Characterisation of Skin Microstructure Under Normal and Atrophied States
- Plain-language title
- Imaging Skin Structure in Atopic Dermatitis Patients Using Light ScansGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 May 2025